Connor P. Hall
YOU?
Author Swipe
View article: Supplementary Figure 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
View article: Supplementary Figure 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.
View article: Suppl Fig 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
View article: Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 1: Changes in body weight of mice treated with vehicle.
View article: Suppl Fig 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
View article: Supplementary Figure 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 3. Analysis of PI3K/AKT/mTOR pathway activity in ALL cell lines.
View article: Supplementary Tables 1 - 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplementary Tables 1 - 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Table 1. Human EFT, RMS, and NB cell lines used for current study. Supplementary Table 2. Median Survival of xenograft mice bearing human pediatric cancer treated with irinotecan or nal-IRI. Supplementary Table 3. Pharmacokin…
View article: Suppl Fig 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
View article: Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 3: Representative pictures of macrophage infiltration in tumors.
View article: Supplementary Methods and figure legends from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Methods and figure legends from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Supplementary Methods and figure legends. Supplementary methods and legends for supplementary figures
View article: Data from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Data from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Purpose: The aim of our study is to evaluate the preclinical therapeutic activity and mechanism of action of BEZ235, a dual PI3K/mTOR inhibitor, in combination with dexamethasone in acute lymphoblastic leukemia (ALL).Experimental Design: T…
View article: Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clini…
View article: Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clini…
View article: Suppl Fig 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 3. Analysis of PI3K/AKT/mTOR pathway activity in ALL cell lines.
View article: Supplementary Figure 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 1. GC Receptor expression and functionality in T- and B-ALL cell lines.
View article: Supplementary Figure 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 6. Mechanism of synergy of BEZ235 plus dexamethasone.
View article: Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 4: Inverse correlation between sensitivity to DNA damaging agents and SLFN11 expression.
View article: Supplementary Figure 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
View article: Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 1: Changes in body weight of mice treated with vehicle.
View article: Supplementary Figure 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
View article: Supplemental Figure 2 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 2 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 2: The effect of plasma caroxylesterase activity on the conversion of CPT-11 to SN-38 in mouse and human plasma.
View article: Supplementary Figure 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
View article: Data from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Data from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Purpose: The aim of our study is to evaluate the preclinical therapeutic activity and mechanism of action of BEZ235, a dual PI3K/mTOR inhibitor, in combination with dexamethasone in acute lymphoblastic leukemia (ALL).Experimental Design: T…
View article: Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 3: Representative pictures of macrophage infiltration in tumors.
View article: Supplementary Figure 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 6. Mechanism of synergy of BEZ235 plus dexamethasone.
View article: Supplementary Methods and figure legends from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Methods and figure legends from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Supplementary Methods and figure legends. Supplementary methods and legends for supplementary figures
View article: Suppl Fig 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.
View article: Suppl Fig 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Suppl Fig 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 1. GC Receptor expression and functionality in T- and B-ALL cell lines.
View article: Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression
Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression Open
Supplementary Figure 4: Inverse correlation between sensitivity to DNA damaging agents and SLFN11 expression.
View article: Supplementary Figure 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Supplementary Figure 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 Open
Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.